drugset / Trial / NCT05893797

A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

NCT05893797

Completed 36 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.

Timeline

Start
2023-10-05
Primary completion
2024-09-16
Completion
2024-09-16

Drugs

EvaluationDrugModalityDoseRoute
Background Insulin Lispro Protein / enzyme biologic